License Fees and Milestone Payments Sample Clauses

License Fees and Milestone Payments. 5.1 The LICENSEE shall make separate payments to MVP and to DUKE according to the following schedule: 1) Execution of this AGREEMENT [***] [***] [***]
Sample 1Sample 2
AutoNDA by SimpleDocs
License Fees and Milestone Payments. NBIX shall make the following payments to BIAL:
Sample 1Sample 2
License Fees and Milestone Payments. 5.1 The LICENSEE shall make separate payments to MVP and to DUKE according to the following schedule: […***…] of U.S. Dollars 1) Execution of this AGREEMENT […***…] […***…] […***…]
Sample 1Sample 2
License Fees and Milestone Payments. Hormos shall pay to Orion license fees and milestones as follows: 6.2.1 A one time payment of fifty thousand EURO (50,000.-) within thirty (30) days of signing of this Agreement. 6.2.2 A one time payment of **** EURO (****) within thirty days (30) days of ************************* ****************************************** ******* ****************** **** is deemed to be obtained after ******. Hormos undertakes to make the **** decision within **** after the **** is obtained. Hormos - Orion SERM Licensing agreement -------------------------------------------------------------------------------- If NO GO decision is made, Hormos is not entitled to develop the compound any further or have the compound developed on behalf of it or sublicense the compound before the payment mentioned in this section 6.2.1 is made. Hormos undertakes to inform its decision to Orion without delays. 6.2.3 A one time payment of **** EURO (****) within thirty (30) days after an NDA for any Product if filed for an indication with, and accepted for filing by, the US FDA, or with any other regulatory authority in any other country or territory of the world, which filing is made by or on behalf of Hormos or any Affiliated Company of Hormos or any sublicensee of Hormos or its Affiliated Company or any other third party for or on Hormos' or its Affiliated Company's or its sublicensee's benefit or behalf or deriving its rights from Hormos or its Affiliated company or sublicensee. 6.2.4 A one time payment of **** EURO **** within thirty days of the NDA approval issued by the FDA, or any approval issued by any other regulatory authority in any country or territory of the world, allowing commercial marketing or sale of any Product. 6.2.5 Hormos shall be responsible for above mentioned (i-iii) payments regardless of whether the respective filing is made by or on behalf of Hormos or any Affiliated Company of Hormos or any sublicensee of Hormos or its Affiliated Company or any other third party, for or on Hormos' or its Affiliated Company's or its sublicensee's benefit or behalf, or deriving its rights from Hormos or its Affiliated company or sublicensee..
Sample 1
License Fees and Milestone Payments. 5.1 LICENSE FEES AND MILESTONE PAYMENTS FOR ASIA AND EUROPE.
Sample 1
License Fees and Milestone Payments. In consideration of the rights, privileges and licenses granted by IMMULOGIC hereunder, HESKA shall pay the license and milestone fees as follows: (a) Initial license fee, nonrefundable and noncreditable against royalties, of [**], due within five (5) business days after execution of this Agreement by both parties; (b) Subject to Section 3.2(c) below, milestone license fees as follows, nonrefundable and noncreditable against royalties, due within fifteen (15) days after each of the following milestones: (i) One-time fee of [**], after the first date that [**]; (ii) One-time fee of [**], after the [**]; (iii) One-time fee of [**], after the [**].
Sample 1
License Fees and Milestone Payments. (a) Licensee shall pay Licensor a License fee in the total amount of $100,000 (the “License Fee”), which License Fee shall be payable as follows: ● The amount of $35,000 in the form of cash for access to the Licensed Technology will be paid by Licensee to Licensor upon the date of execution of this Agreement; ● The amount of $30,000 in the form of cash shall be due within one hundred eighty (180) days from the date of execution of this Agreement; and ● The amount of $35,000 in the form of cash or (at the option of Licensee) common stock of Licensee, shall be due within one (1) year from the date of execution of this Agreement. (b) With respect specifically to Pharmaceutical Licensed Products, milestone payments (the “Milestone Payments”) may be paid in cash or (at the option of Licensee) common stock of Licensee pursuant to the following: ● A milestone payment of $100,000 shall be due upon approval of filing by each Regulatory Authority of each Pharmaceutical Licensed Product; ● A milestone payment of $100,000 shall be due upon approval by each Regulatory Authority of each Pharmaceutical Licensed Product; ● A milestone payment of $50,000 shall be due upon achievement of $10,000,000 of cumulative Net Sales for any and all of the Licensed Products (for clarity purposes, this payment is a one-time only payment) in the Territory; ● A milestone payment of $50,000 shall be due upon achievement of $25,000,000 of cumulative Net Sales for any and all of the Licensed Products (for clarity purposes, this payment is a one-time only payment) in the Territory; ● A milestone payment of $50,000 shall be due upon achievement of $50,000,000 of cumulative Net Sales for any and all of the Licensed Products (for clarity purposes, this payment is a one-time only payment) in the Territory. (c) For the purposes of this Section 5.1, if License Fees and/or Milestone Payments are paid with common stock of Licensee, the shares shall not be registered under federal securities laws and shall be valued using the weighted average over the five (5) trading days immediately preceding the due date of the payment.
Sample 1
AutoNDA by SimpleDocs
License Fees and Milestone Payments 
Sample 1Sample 2Sample 3See All (5)

Related to License Fees and Milestone Payments

  • Milestone Payments In the event that any Sellers believe that any Additional Milestone has been achieved during the Post-Closing Milestone Period, the Sellers’ Representative shall provide notice of such achievement to Purchaser. If Purchaser determines in its sole and reasonable discretion that such Additional Milestone has been achieved during the Post-Closing Milestone Period, then within thirty (30) days of such notice from Sellers’ Representative or, if earlier, within thirty (30) days of Purchaser’s determination that such Additional Milestone has been achieved, Purchaser shall notify Sellers’ Representative of its determination and pay to Sellers the Additional Milestone Payment payable in respect of such Additional Milestone. If Sellers’ Representative delivers such a notice and Purchaser determines, in its sole and reasonable discretion, that the applicable Additional Milestone has not been achieved, then, within thirty (30) days of Sellers’ Representative’s notice Purchaser shall notify Sellers’ Representative of such determination. If Sellers’ Representative believes that Sellers are entitled to payment of all or any portion of an Additional Milestone Payment hereunder which they have not received within thirty (30) days following the achievement of the Additional Milestone for which payment is due, Sellers’ Representative may, not later than twelve (12) months following the achievement of such Additional Milestone, deliver to Purchaser a notice setting forth Sellers’ Representative’s determination that all or a portion of such Additional Milestone Payment is due under this Agreement (the “Post-Closing Assessment Notice”). If Sellers’ Representative does not deliver to Purchaser a Post-Closing Assessment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission. Notice within such twelve (12) month period, then Sellers shall have been deemed to agree that the Additional Milestone has not been met and no payment with respect to such Additional Milestone is due to Sellers hereunder and Sellers shall have no further rights to such Milestone Payment or any portion thereof. Such Post-Closing Assessment Notice may be delivered before or after the expiration of the Post-Closing Milestone Period without affecting Sellers’ rights to the applicable Milestone Payment, provided that that applicable Additional Milestone was actually achieved prior to the expiration of such Post-Closing Milestone Period. If Purchaser shall object to Sellers’ determination that a Additional Milestone has been achieved as set forth in the Post-Closing Assessment Notice, then Purchaser shall deliver a dispute notice (a “Post-Closing Milestone Dispute Notice”) to Sellers’ Representative within fifteen (15) days following Sellers’ Representative’s delivery of the Post-Closing Assessment Notice. A representative of Purchaser, on the one hand, and the Sellers’ Representative, on the other, shall attempt in good faith to resolve any such objections within fifteen (15) days of the receipt by Sellers of the Post-Closing Milestone Dispute Notice. If no Post-Closing Milestone Dispute Notice is delivered within the fifteen (15) day time period, then Sellers’ determination that the Additional Milestone has been achieved, and that the amount of the Milestone Payment specified in the Post-Closing Milestone Dispute Notice is due hereunder, shall be deemed to be accepted and Purchaser shall pay to Sellers those amounts set forth in the Post-Closing Assessment Notice no later than five (5) days after the expiration of such fifteen (15) day time period.

  • Milestone Fees Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent & Technology License Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) of the Patent & Technology License Agreement are achieved.

  • Milestone Payment The first time Net Sales in the Territory in a Royalty Period exceed US$[***] ([***] dollars) US$[***] ([***] dollars)

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Development Milestone Payments (i) In addition to the Closing Date Merger Consideration (less the Remaining Option Consideration and Rights Proceeds Amount, if any) and any Net TNF Sales Payments (as defined below), upon the attainment of the development ** Portions of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. milestones set forth below (each, a “Development Milestone”), Parent shall, or shall cause the Surviving Corporation to, [**] after the occurrence of each Development Milestone, deliver to the Paying Agent (for further payment to the holders of Stock Certificates and Stock Agreements outstanding immediately prior to the Effective Time), via wire transfer of immediately available funds, the respective amounts set forth below minus, in each case, the applicable Contingent Consideration Distribution Fee associated therewith and any amount designated by the Stockholders’ Representatives to be placed in the Administrative Expense Account (each, a “Development Milestone Payment” and collectively, the “Development Milestone Payments”): (A) Upon FDA approval of Reslizumab for the treatment of eosinophilic esophagitis, a cash payment of [**]; (B) Upon marketing authorization of Reslizumab for the treatment of eosinophilic esophagitis being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; (C) If Res 5-0010 Asthma Study Completion has not occurred on or prior to the Closing Date, then upon the occurrence of the Res 5-0010 Asthma Study Completion, a cash payment of $50,000,000 (fifty million dollars) (the “Res 5-0010 Asthma Payment”); (D) Upon FDA approval of Reslizumab for any asthma indication, a cash payment of [**]; (E) Upon marketing authorization of Reslizumab for the treatment of any asthma indication being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; and (F) Upon FDA approval of an Oral Anti-TNF Product, a cash payment of [**].

  • License Fees and Royalties Consistent with the applicable U.S. DOT Common Rules, the Recipient agrees that license fees and royalties for patents, patent applications, and inventions produced with federal assistance provided through the Underlying Agreement are program income, and must be used in compliance with federal applicable requirements.

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • License Fees If so provided in the Prospectus, the Depositor may enter into a Licensing Agreement (the "Agreement") with a licensor (the "Licensor") described in the Prospectus in which the Trust(s), as consideration for the licenses granted by the Licensor for the right to use its trademarks and trade names, intellectual property rights or for the use of databases and research owned by the Licensor, will pay a fee set forth in the Agreement to the applicable Licensor or the Depositor to reimburse the Depositor for payment of the expenses. If the Agreement provides for an annual license fee computed in whole or part by reference to the average daily net asset value of the Trust assets, for purpose of calculating the accrual of estimated expenses such annual fee shall accrue at a daily rate and the Trustee is authorized to compute an estimated license fee payment (i) until the Depositor has informed the Trustee that there will be no further deposits of additional Securities, by reference to an estimate of the average daily net asset value of the Trust assets which the Depositor shall provide the Trustee, (ii) thereafter and during the calendar quarter in which the last business day of the period described in clause (i) occurs, by reference to the net asset value of the Trust assets as of such last business day, and (iii) during each subsequent calendar quarter, by reference to the net asset value of the Trust assets as of the last business day of the preceding calendar quarter. The Trustee shall adjust the net asset value (Trust Fund Evaluation) as of the dates specified in the preceding sentence to account for any variation between accrual of estimated license fee and the license fee payable pursuant to the Agreement, but such adjustment shall not affect calculations made prior thereto and no adjustment shall be made in respect thereof. (17) Sections 2.05(a) and 2.05(b) are hereby amended and replaced in their entirety with the following:

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Milestone Event Milestone Payment [***] [***]

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!